Zometa Articles
Overview of Novartis' patent losses from GlobalData
11 October 2012
Denosumab superior to zoledronic acid for breast cancer patients with bone metastases
15 August 2012
Novartis’ Zometa fails to meet Ph III primary endpoint in early breast cancer, stalling this indication; but Afinitor looks good
10 December 2010
Novartis once-yearly Reclast preserves bone mass, provides fracture protection in postmenopausal osteoporosis, long term data show
18 October 2010
ASCO highlights include cancer drug news from Pfizer, Roche, Sanofi, Merck KGaA, Novartis and Eisai
7 June 2010
Analysts see positive future for Amgen’s bone metastases drug denosumab following strong Ph III data
10 February 2010
Novartis posts 50% 4th-qtr 2009 profits rise and promotes drugs chief Jimenez to CEO; other top changes
26 January 2010
Novartis aims to hold global position in oncology, with new drugs and indications, R&D meeting told
9 December 2009
Cancer pain drug market, fueled by opioids, will increase from $2.3 billion in 2008 to $3.7 billion in 2018
25 November 2009
Amgen’s pipeline boosted by new denosumab data
23 September 2009
Novartis' 1st-qtr 2009 results boosted by new products
24 April 2009
Novartis drug cuts breast cancer death by 36%
2 March 2009
Novartis speeds R&D ahead of Diovan loss
12 January 2009
Zometa plus chemo reduces breast tumor size pre-surgery
22 December 2008
Novartis profit up 32% in 3rd qtr
27 October 2008
Zometa cuts risk of early-stage breast cancer recurrence
22 September 2008
Novartis withdraws EU label extension for Zometa
26 November 2007
Novartis' 1st-qtr 2007 profit up 11% to $2.17B on strong sales of cancer drugs and Diovan
30 April 2007
Novartis' Zometa fares well vs Aredia
19 June 2006
Roche's Bondronat demonstrates safety
3 April 2006
Novartis launches Zometa in Japan
7 February 2005
Novartis says yes to Aventis merger talks
26 April 2004
Roche Bondronat: clarifications
29 March 2004
Novartis' sales on track in third quarter; profits rise 7% as Diovan, Gleevec deliver
27 October 2003
EMEA updates label for Novartis' Zometa
23 June 2003
Data back Zometa's role in prostate cancer
5 May 2003
Profits flat at Novartis despite sales growth
21 April 2003
Zometa effective long-term, says CPMP
3 March 2003
Novartis sales grow 12% in 2nd qtr
29 July 2002
Zometa backed by CPMP
6 May 2002
Novartis gets OK for new Zometa use
4 March 2002
Stock Commentary - Europe
4 March 2002
Double-digit turnover growth for Novartis in 2001
11 February 2002
Novartis' Zometa backed for treatment of bone metastases in USA
11 February 2002
FDA stance on Zometa
4 February 2002
Roche, GSK link up on osteoporosis drug
7 December 2001
Update: Novartis files new indication for Gleevec in USA
24 October 2001
Novartis reports new Zometa data
22 October 2001
Stock Commentary - Europe
30 August 2001
Novartis files further Zometa indication
24 August 2001
Novartis' Ritadex is "approvable" in USA
23 August 2001
Novartis' Zometa finally wins FDA approval
22 August 2001
New Zometa indication filed with EMEA
8 August 2001
Novartis 1st qtr pharma sales rise 13%
19 April 2001
Stock Commentary - Europe
5 April 2001
Novartis' Zometa gets European approval
30 March 2001
Novartis expects five new products to drive growth in 2001
15 February 2001
Healthy harvest of New Chemical Entities in 2000
2 January 2001
Novartis R&D day updates prospects for key pipeline drugs
7 December 2000
Novartis' Zometa cleared in Switzerland
7 December 2000
Approvable letter for Novartis' Zometa
28 September 2000
Approvable letter for Novartis' Zometa
22 September 2000
Novartis wins first approval for Zometa
30 August 2000
Novartis says 25% chance Zelmac NDA will not be accepted
22 February 2000
Novartis' Zometa designated for priority review by FDA
10 February 2000
Novartis seeks US, European Starlix OK
23 December 1999
Novartis Trileptal approvable in USA; firm building broad franchise in
30 September 1999
Novartis upbeat at biannual R&D update
23 September 1999
Showing 1-94 of 94 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
